Collegium Pharma

$19.79 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Collegium Pharma

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting. Xtampza ER is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. ONSOLIS is a Transmucosal Immediate-Release Fentanyl (TIRF) film indicated for the management of breakthrough pain in cancer patients (BTPc), 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

Stock Analysis

last close $19.35
1-mo return 5.6%
3-mo return 36.1%
avg daily vol. 226.47T
52-week high 22.89
52-week low 14.04
market cap. $686M
forward pe 3
annual div. -
roe 23.4%
ltg forecast -
dividend yield -
annual rev. $273M
inst own. -
baraka

Subscribe now for daily local and international financial news

Subscribe